Home › Trials › NCT06846320

Assessing the safety and effectiveness of ABBV-932 for anxiety treatment

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies

PHASE2 · AbbVie · NCT06846320

This study is testing a new drug called ABBV-932 to see if it can help adults with generalized anxiety disorder who aren't feeling better with their current antidepressants.

Quick facts

PhasePHASE2
Study typeInterventional
Enrollment315 (estimated)
Ages18 Years to 65 Years
SexAll
SponsorAbbVie (industry)
Locations52 sites (Huntsville, Alabama and 51 other locations)
Trial IDNCT06846320 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and efficacy of ABBV-932, an investigational drug, when added to existing antidepressant therapies in adults with generalized anxiety disorder (GAD) who have not responded adequately to their current treatment. Participants will be randomly assigned to receive either ABBV-932 or a placebo alongside their prescribed antidepressants for a duration of 6 weeks, followed by a 4-week follow-up period. The study aims to enroll approximately 315 participants across 50 sites in the United States and Puerto Rico.

Who should consider this trial

Good fit: Ideal candidates are adults diagnosed with generalized anxiety disorder who are currently on FDA-approved antidepressant therapies but have experienced inadequate relief.

Not a fit: Patients with significant depression or those who have recently been diagnosed with major depression may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new adjunctive treatment option for patients with GAD who do not respond adequately to standard antidepressant therapies.

How similar studies have performed: Previous studies have explored adjunctive treatments for GAD, but the specific use of ABBV-932 in this context is novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for generalized anxiety disorder (GAD) confirmed by the Mini International Neuropsychiatric Interview (MINI).
* Currently taking one of the Food and Drug Administration (FDA) approved antidepressant therapies (ADT) for GAD (i.e., escitalopram, paroxetine, duloxetine, or venlafaxine ER) with an inadequate response to an adequate dose (per label) and duration (\>= 8 weeks) as verified by a baseline Hamilton Anxiety Rating Scale (HAM-A) total score \>= 20 and Clinical Global Impression of Severity Scale (CGI-S GAD) \>= 4.

Exclusion Criteria:

* Have a Montgomery-Åsberg Depression Rating Scale (MADRS) score \>= 20.
* New diagnosis or exacerbation of major depression in the last 6 months.

Where this trial is running

Huntsville, Alabama and 51 other locations

+2 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Generalized Anxiety Disorder, LEGATO -, ABBV-932

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.